- Home
- JFR vs XNCR Comparison
JFR vs XNCR Comparison
Compare JFR & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFR
- XNCR
- Stock Information
- Founded
- JFR 2004
- XNCR 1997
- Country
- JFR United States
- XNCR United States
- Employees
- JFR N/A
- XNCR N/A
- Industry
- JFR Trusts Except Educational Religious and Charitable
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- JFR Finance
- XNCR Health Care
- Exchange
- JFR Nasdaq
- XNCR Nasdaq
- Market Cap
- JFR 1.1B
- XNCR 1.1B
- IPO Year
- JFR N/A
- XNCR 2013
- Fundamental
- Price
- JFR $8.43
- XNCR $12.87
- Analyst Decision
- JFR
- XNCR Strong Buy
- Analyst Count
- JFR 0
- XNCR 8
- Target Price
- JFR N/A
- XNCR $34.13
- AVG Volume (30 Days)
- JFR 621.7K
- XNCR 585.5K
- Earning Date
- JFR 01-01-0001
- XNCR 05-08-2025
- Dividend Yield
- JFR 11.31%
- XNCR N/A
- EPS Growth
- JFR N/A
- XNCR N/A
- EPS
- JFR N/A
- XNCR N/A
- Revenue
- JFR N/A
- XNCR $110,493,000.00
- Revenue This Year
- JFR N/A
- XNCR $4.14
- Revenue Next Year
- JFR N/A
- XNCR $25.12
- P/E Ratio
- JFR N/A
- XNCR N/A
- Revenue Growth
- JFR N/A
- XNCR N/A
- 52 Week Low
- JFR $7.61
- XNCR $12.81
- 52 Week High
- JFR $8.82
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- JFR 38.84
- XNCR 19.07
- Support Level
- JFR $8.41
- XNCR $13.42
- Resistance Level
- JFR $8.53
- XNCR $14.02
- Average True Range (ATR)
- JFR 0.07
- XNCR 0.72
- MACD
- JFR 0.00
- XNCR 0.02
- Stochastic Oscillator
- JFR 12.94
- XNCR 1.90
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.